ebov

EBOV-IN-1 is an adamantane dipeptide piperazine inhibitor against Ebola virus (EBOV) that inhibits EBOV infection and suppresses pseudotypic EBOV infection.

EBOV-IN-10 is an orally active inhibitor of the Ebola virus (EBOV) with an EC50 value of 0.19 μM.

EBOV-GP-IN-1 (Compound 28) is a potent inhibitor of Ebola virus entry, targeting the Ebola virus envelope glycoprotein (EBOV-GP) with an IC50 of 0.05 μM.

EBOV-IN-C31 is a novel PP1-targeting Ebola Virus (EBOV) inhibitor with improved pharmacological properties.

EBOV-IN-3 (compound 9), a benzothiazepine compound, and EBOV-IN-6 exhibit notable anti-pEBOV activity, with the latter demonstrating an IC 50 value of 0.37 μM [1].

EBOV-IN-4 (compound 12), a benzothiazepine, acts as a potent inhibitor against the Ebola virus (EBOV), displaying 64.9% inhibitory activity against EBOV-GP-pseudotype virus (pEBOV) at a concentration of 10 μM. It is, however, inactive against ASFV [1].

EBOV-IN-5 (compound 14) serves as an antiviral agent targeting the Ebola virus (EBOV) by disrupting its entry mechanism into host cells. It specifically blocks the interaction between the EBOV glycoprotein EBOV-GPcl and the essential host receptor NPC1, which is crucial for the virus's fusion and entry into the cell. [7] [1]

EBOV-IN-7 (compound 26) acts as an inhibitor against the Ebola virus EBOV, displaying an IC 50 value of 2.04 μM against pEBOV (EBOV-GP pseudotyped virus). It also obstructs the EBOV-GPcl NPC1 interaction and exhibits inhibitory effects on cancer cells. [8] [1]

EBOV-IN-8 (Compound 30) effectively inhibits the Ebola pseudotyped virus (pEBOV) with an inhibition concentration (IC 50) of 62.1% at a dosage of 10 μM [1].

K777 is a potent, orally active, and irreversible inhibitor of cysteine protease, functioning as a potent CYP3A4 inhibitor (IC50 = 60 nM) and a selective CCR4 antagonist, which inhibits chemotaxis. K777 irreversibly inhibits Cruzain, the major cysteine protease of Trypanosoma cruzi, and cathepsins B and L, targeting cathepsin-mediated cell entry and exhibiting broad-spectrum antiviral activity. It inhibits EBOV and SARS-CoV pseudovirus entry with IC50 values of 0.87 nM and 0.68 nM, respectively.

SP187 (MON-DNJ) is a host-targeted iminosugar. It has anti-filovirus infection activity.SP187 is used for therapeutic use against influenza and dengue viruses.

Retro-2 (2-{[(5-methyl-2-thienyl)methylene]amino}) is a plant toxin ricin inhibitor, itprotects HeLa cells against Ricin, Stx1 and Stx2, selectively blocks retrograde toxin trafficking at the early endosome-TGN (trans-Golgi network) interface.

Toremifene (GTx 006) is a selective estrogen-receptor modulator (SERM).

FGI-106 is a potent, broad-spectrum inhibitor demonstrating activity against various viruses, including Ebola, Rift Valley Fever, and Dengue Fever, exhibiting EC50 values of 100 nM, 800 nM, and 400-900 nM, respectively. Furthermore, it effectively inhibits non-hemorrhagic fever viruses such as HCV and HIV-1, with EC50s of 200 nM and 150 nM, respectively.

FGI-106 tetrahydrochloride demonstrates potent inhibitory activity across a broad spectrum of viruses, including those causing hemorrhagic fevers such as Ebola, Rift Valley, and Dengue Fever, with half-maximal effective concentrations (EC50s) of 100 nM, 800 nM, and 400-900 nM, respectively. Additionally, it effectively inhibits non-hemorrhagic fever viruses, notably HCV and HIV-1, with EC50s of 200 nM and 150 nM, respectively, indicating its broad-spectrum antiviral potential.

R 59-022 (DKGI-I) is a diacylglycerol kinase (DGK) inhibitor and a 5-HT Receptor antagonist that blocks filovirus internalization in host cells. R 59-022 activates protein kinase C (PKC), inhibits intestinal smooth muscle contractility, and enhances O2- production induced by 1-oleoyl-2-acetylglycerol.

Antiviralagent 59 (compound 58) is a selective antiviral agent with drug-like properties, capable of inhibiting a broad spectrum of filoviruses. It demonstrates low off-target activity and inhibitory effects against replicative forms of Ebola virus (EBOV), Sudan virus (SUDV), and Marburg virus (MARV).

Anti-virus agent 1 (compound 4i), a phosphoramidate prodrug of GS-5734, exhibits potent antiviral efficacy and is primarily utilized in coronavirus and Ebola virus (EBOV) research.

Cephaeline hydrochloride, a phenolic alkaloid found in Indian Ipecac, effectively inhibits the infection of viruses ZIKV and EBOV.

ZINC09410451 is a potent ebolavirus (EBOV) inhibitor.

ZINC32540717 is a potent ebolavirus (EBOV) inhibitor.

CP19, a histamine receptor antagonist, serves as an entry inhibitor for Ebolavirus (EBOV) and Marburgvirus (MARV), with inhibitory concentrations (IC50s) of 3.4 μM for EBOV and 29.5 μM for MARV, and selective index (SI) values of 29.4 for EBOV and 3.4 for MARV, indicating its antiviral activity against these viruses.

Eritoran, a Toll-like receptor 4 (TLR4) antagonist, effectively protects mice from lethal infections caused by viruses such as the Ebola virus (EBOV) and Marburg virus (MARV). By decreasing granulocytosis levels, Eritoran may reduce the severity of cytokine storms, thereby inhibiting the pathogenesis of filovirus infections [1].

Atoltivimab (REGN3470), also known as maftivimab odesivimab (Inmazeb), represents the first monoclonal antibody approved by the Food and Drug Administration (FDA) to combat Zaire ebolavirus (EBOV) infection [1].